Abbott Laboratories on Wednesday, Oct. 21, cut its 2026 sales growth forecast after softer-than-expected demand for its medical devices, Reuters reported. The company now projects full-year comparable sales growth of about 6.0%, Abbott said, compared with its prior expectation of 6.5% to 7.5%, according to Reuters.

Third-quarter sales rose 14.5% on a reported basis and 7.0% on a comparable basis, the company said. Comparable growth includes prior- and current-year sales of Exact Sciences, which Abbott acquired on March 23, 2026.

Adjusted earnings per share were $1.42, in line with analysts’ average estimate, according to LSEG data cited by Reuters. Abbott reaffirmed the midpoint of its full-year adjusted EPS guidance and tightened the range to $5.50 to $5.55.

Worldwide nutrition sales rose 5.1% on a reported basis, driven by growth of nearly 9% in pediatric nutrition, the company said.